Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1402959 | 0.98 | GAA (0.53) | GAANOX1POLBCYP3A4MAPK1 | |
| SCHEMBL6821181 | 0.82 | GAA (0.59) | GAAPOLBCYP3A4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL403976 | 0.80 | GAA (0.58) | GAAPOLBCYP3A4MAPTALDH1A1 | |
| SCHEMBL30780064 | 0.79 | NOX1 (0.55) | GAANOX1POLBCYP3A4MAPK1 | |
| SCHEMBL28748358 | 0.79 | NOX1 (0.55) | GAANOX1POLBCYP3A4MAPK1 | |
| SCHEMBL22838153 | 0.79 | NOX1 (0.55) | GAANOX1POLBCYP3A4MAPK1 | |
| SCHEMBL9233011 | 0.79 | NOX1 (0.55) | GAANOX1POLBCYP3A4MAPK1 | |
| SCHEMBL11408277 | 0.77 | NOX1 (0.58) | GAANOX1POLBMAPK1MAPT | |
| SCHEMBL1010790 | 0.76 | RAPGEF4 (0.56) | GAAMAPTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL29573961 | 0.76 | CA1 (0.53) | GAACYP3A4MAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| EP-3807266-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| EP-0673781-A1 | Recording sheets containing amine salts and quaternary choline halides | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
| US-4293553-A | ANTITHROMBOTIC AGENT | Ishikawa, Masayuki (JP) | 1981-10-06 | — | — | US | disclosed |
| US-4094906-A | INSECTICIDES AND MITICIDES | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4069377-A | Polymerization of ethylenically unsaturated monomers employing secondary-aliphatic α-substituted azoalkanes | PENNWALT CORPORATION | 1978-01-17 | — | — | US | disclosed |
| US-4028344-A | FOAMING AGENTS, FREE RADICAL INITIATORS | PENNWALT CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
| US-4025502-A | POLYMERIZATION CATALYSTS, CURING AGENTS | PENNWALT CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
| US-3987234-A | ACRYLIC ESTER POLYMERS | HENKEL & CIE G.M.B.H. (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | GAA 89/4885NOX1 621/4885POLB 4391/4885 |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | GAA 1088/4885NOX1 1813/4885POLB 2137/4885 |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | GAA 1088/4885NOX1 1813/4885POLB 2137/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | GAA 1088/4885NOX1 1813/4885POLB 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.